Leukemia  >>  Phase 1
Welcome,         Profile    Billing    Logout  

406 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukemia
NCT04659616: Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Recruiting
1
32
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin, Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C, Electrocardiography, ECG, EKG, Pemigatinib, INCB054828, Pemazyre
OHSU Knight Cancer Institute, Incyte Corporation, Oregon Health and Science University
Acute Myeloid Leukemia
08/25
02/26
03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Recruiting
1
160
Europe, Canada, US
SL-172154, Azacitidine, Venetoclax
Shattuck Labs, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
04/25
12/25
NCT05758610: A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Recruiting
1
60
RoW
ETH-155008, Study drug
Shengke Pharmaceuticals (Jiangsu) Limited, China
NHL, Adult, AML, Adult Recurrent
12/25
06/26
NCT06234904: Study of IBR733 Cell Injection in Acute Myeloid Leukemia

Not yet recruiting
1
18
RoW
IBR733 Cell Injection
Imbioray (Hangzhou) Biomedicine Co., Ltd., The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
02/25
08/25
AMpLify, NCT06128044: CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
70
US
CB-012, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
11/27
04/28
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Active, not recruiting
1
55
US
Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile
Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
06/24
09/24
NCT04682808: A Study of FCN-338 in Patients With Chronic CLL/SLL

Recruiting
1
79
RoW
FCN-338
Fochon Pharmaceuticals, Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/24
06/24
PLAT-08, NCT05105152: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Recruiting
1
18
US
SC-DARIC33
Seattle Children's Hospital, 2seventy bio
Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
02/26
01/41
NCT04803929: Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

Recruiting
1
25
RoW
anti-ILT3 CAR-T
Carbiogene Therapeutics Co. Ltd., Zhejiang Provincial People's Hospital
AML M4, AML M5
03/24
03/26
NCT05190471: A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Recruiting
1
48
US
BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide, Liposomal Bcl-2; L-Bcl-2, Decitabine (in combination with BP1002), Decitabine
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
03/24
09/24
PRESERVE, NCT05170828: Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Withdrawn
1
30
NA
Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Total Body Irradiation, TBI, Busulfan, Busulfelx, Mesna, Mesnex, Sirolimus, Mycophenolate Mofetil, MMF, Filgrastim, G-CSF, Bone Marrow Transplant, Hematopoietic Stem Cell Transplant
Ossium Health, Inc., Center for International Blood and Marrow Transplant Research
Acute Leukemia, Myelodysplastic Syndromes, T-lymphoblastic Lymphoma, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia
03/24
11/24
NCT05759793: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Recruiting
1
12
RoW
CAR-T (CAR-GPRC5D)
Nanjing IASO Biotechnology Co., Ltd., Ruijin Hospital
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
03/24
03/25
NCT06326697: Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)

Not yet recruiting
1
32
NA
Azacitidine, Onureg
Hikma Pharmaceuticals LLC
Acute Myeloid Leukaemia
01/25
03/25
NCT06191978: A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Suspended
1
58
US
ASTX727, Inqovi, Venetoclax, ABT-199, GDC-0199
M.D. Anderson Cancer Center, Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia
12/28
12/28
NCT05907603: Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

Recruiting
1
18
RoW
RD13-02 cell infusion
Kai Lin Xu，MD, Nanjing Bioheng Biotech Co., Ltd.
Neoplasms, Hematologic Neoplasms, Hematologic Diseases
03/24
03/25
NCT05690425: A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML

Recruiting
1
13
RoW
BC3402 Injection, not have
Biocity Biopharmaceutics Co., Ltd.
Hematologic Malignancy
03/24
06/24
BHCT-RD13-02-02, NCT05716113: CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

Recruiting
1
22
RoW
RD13-02 cell infusion
He Huang, Nanjing Bioheng Biotech Co., Ltd.
Neoplasms, Hematologic Neoplasms, Neoplasms by Site, Hematologic Diseases
03/24
05/25
TTI-622-01, NCT03530683: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Checkmark First patient dosed in combination with azacitidine for TP53-mutated AML
Aug 2021 - Aug 2021: First patient dosed in combination with azacitidine for TP53-mutated AML
Checkmark Data from trial for lymphoma
Apr 2021 - Apr 2021: Data from trial for lymphoma
Active, not recruiting
1
177
US
Maplirpacept (PF-07901801), SIRPα-IgG4 Fc, TTI-622, Azacitidine, VIDAZA, Venetoclax, VENCLEXTA, Carfilzomib, KYPROLIS, Dexamethasone, Anti-CD20 Targeting agent, Ruxience or Rituxan, Isatuximab, Sarclisa
Pfizer
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
09/24
09/24
NCT05006040: HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL

Terminated
1
1
US
Hybrid Closed Loop System, Tandem Control-IQ Professional Hybrid Closed Loop system
University of Colorado, Denver, Children's Hospital Colorado, DexCom, Inc., Tandem Diabetes Care, Inc., National Cancer Institute (NCI)
High Risk Acute Lymphoblastic Leukemia
06/22
08/23
NCT02787369: ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Active, not recruiting
1
3
US
ACY-1215, Ricolinostat, Ibrutinib, Imbruvica, Idelalisib, Zydelig
Dana-Farber Cancer Institute, Acetylon Pharmaceuticals Incorporated
Recurrent Chronic Lymphoid Leukemia
04/26
04/27
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Recruiting
1
186
US
OrcaGraft (Orca-Q)
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
04/26
04/28
NCT04578600: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Active, not recruiting
1
8
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Oral Azacitidine, CC-486
Joseph Tuscano, National Cancer Institute (NCI), Celgene
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
04/24
12/24
AUGMENT-102, NCT05326516: A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from AUGMENT-102 trial for relapsed/refractory leukemias
Active, not recruiting
1
30
Canada, US
Revumenib, SNDX-5613, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Syndax Pharmaceuticals
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
05/24
06/24
NCT06347458: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

Not yet recruiting
1
24
NA
BG1805
Guangzhou Bio-gene Technology Co., Ltd
Leukemia, Acute Myeloid Leukemia
04/27
08/27
NCT05396859: Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

Recruiting
1
12
US
Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Laboratory Biomarker Analysis
OHSU Knight Cancer Institute, Oregon Health and Science University, Genentech, Inc., Taiho Oncology, Inc.
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/24
06/25
NCT06177067: Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting
1
24
US
Revumenib, SNDX-5613, Venetoclax, Venclextra®, Azacitidine, VIDAZA®, 5-azacitidine, intrathecal (IT) chemotherapy, ITMHA, methotrexate/hydrocortisone/cytarabine, Cytarabine, Ara-C, Cytosar®, Methotrexate, MTX, Trexall®
St. Jude Children's Research Hospital, Syndax Pharmaceuticals
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
01/26
07/26
NCT06297941: Study of REM-422 in Patients With AML or Higher Risk MDS

Recruiting
1
100
US
REM-422
Remix Therapeutics
Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory
03/26
06/27
NCT03547115: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Checkmark Data from trial for r/r B-cell malignancies or AML at ASH 2021
Nov 2021 - Nov 2021: Data from trial for r/r B-cell malignancies or AML at ASH 2021
Checkmark Initiation of combination trial in B cell malignancies
Jun 2018 - Jun 2018: Initiation of combination trial in B cell malignancies
Recruiting
1
100
US
voruciclib monotherapy, ME-522, voruciclib and venetoclax, VENCLEXTA®
MEI Pharma, Inc.
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
04/24
03/25
Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
1
255
US
Orca-T
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
07/24
07/26
NCT04081259: LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

Recruiting
1
42
US
LY3214996
Dana-Farber Cancer Institute, Eli Lilly and Company
Acute Myeloid Leukemia
02/24
04/25
WUN101-01, NCT05470140: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Recruiting
1
24
US, RoW
WU-NK-101
Wugen, Inc.
Acute Myeloid Leukemia
04/24
12/25
NCT04803123: Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL

Terminated
1
3
US
Copanlisib
Dorothy Sipkins, MD, PhD, Bayer
Leukemia, Acute Lymphocytic
04/23
04/23
NCT05386576: A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Active, not recruiting
1
12
US
Venetoclax
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Acute Lymphoblastic Leukemia
05/25
05/25
NCT05320809: Study of 3D189 in Patients With Hematologic Malignancies

Active, not recruiting
1
15
RoW
3D189
3D Medicines
Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome
05/24
12/24
NCT05406817: Study of Radiolabeled Revumenib in Adults With Acute Leukemia

Recruiting
1
8
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Acute Leukemia
05/24
09/24
NCT06226571: A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

Recruiting
1
76
US
SNDX-5613, Chemotherapy Regimen, HiDAC
Syndax Pharmaceuticals
Acute Myeloid Leukemias
02/27
02/27
NCT00788684: Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Checkmark P1 data (Lymphoid cancer, +rituximab)
Dec 2010 - Dec 2011: P1 data (Lymphoid cancer, +rituximab)
Active, not recruiting
1
29
US, RoW
rituximab, Rituxan, ABT-263, navitoclax
AbbVie, Genentech, Inc.
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
01/25
01/25
NCT02303821 / 2014-001633-84: Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Active, not recruiting
1
130
Europe, Canada, US, RoW
Carfilzomib, PR-171, PR171, Kyprolis® (carfilzomib) for Injection, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin
Amgen, Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator, Innovative Therapies For Children with Cancer Consortium
Acute Lymphoblastic Leukemia (ALL)
07/24
07/24
CR109124, NCT05453903: A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Recruiting
1
150
Europe, US, RoW
JNJ-75276617, Venetoclax (VEN), Azacitidine (AZA), Cytarabine, Daunorubicin or Idarubicin
Janssen Research & Development, LLC
Leukemia, Myeloid, Acute
05/24
03/26
NCT06285890: Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia

Recruiting
1
18
US
HC-7366, Azacitidine, Ladakamycin, AZA-CR, NSC-102816, Azacytidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, Venetoclax, ABT-199, GDC-0199
M.D. Anderson Cancer Center, HiberCell, Inc.
Acute Myeloid Leukemia
12/27
12/29
GLB-001-02, NCT06378437: A Study of GLB-001 in Patients With Myeloid Malignancies

Recruiting
1
108
RoW
GLB-001, GLB-C183-A-2
Hangzhou GluBio Pharmaceutical Co., Ltd.
Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy
12/26
12/27
NCT06419634: Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
1
35
Canada, US
BMS-986497
Bristol-Myers Squibb
Acute Myeloid Leukemia, Myelodysplastic Syndrome
02/27
09/30
NCT05381181: Safety and Efficacy Evaluation of Next-generation CD19-UCART

Not yet recruiting
1
20
NA
CD19-UCART
Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
05/24
05/26
KQ-2002-XC001, NCT06445803: CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Recruiting
1
48
RoW
KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）
Rong Tao, Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
10/26
12/26
TG-1701-101, NCT03671590: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Checkmark From a trial for CLL at EHA 2020
Jun 2020 - Jun 2020: From a trial for CLL at EHA 2020
Terminated
1
172
Europe, RoW
TG-1701, Umbralisib, TGR-1202, Ublituximab, TG-1101
TG Therapeutics, Inc.
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
05/24
05/24
NCT05088356: Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Recruiting
1
40
US
Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Beneflur, SH T 586, fludarabine monophosphate, Melphalan, Melphalanum, CliniMACS CD34 Reagent System, Tacrolimus, Prograf, Advagraf, fujimycin, Cyclophosphamide, alkylating agent, Plerixafor, Mozobil, AMD 3100, LM-3100, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, filgrastim XM02, Thiotepa, Tepandina, Mycophenolate Mofetil (MMF), CellCept, Ruxolitinib, Jakafi
Stanford University, Orca Biosystems, Inc.
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
12/25
12/25
NCT05528887: Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Recruiting
1
10
RoW
Autologous CAR-T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan
The Affiliated People's Hospital of Ningbo University, UTC Therapeutics Inc.
Relapsed/Refractory Hematological Malignancies, Lymphoma, Myeloma, Leukemia
06/24
06/26
NCT06398457: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Not yet recruiting
1
8
NA
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score, JH-DSA Semi-Quant Screen Score, JH-DSA Semi-Quant Response Score
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Janssen Research & Development, LLC
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
06/26
12/26
BYON4413.001, NCT06359002: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Recruiting
1
100
Europe
BYON4413
Byondis B.V.
Relapsed / Refractory AML, Relapsed / Refractory MDS
12/26
03/27
CYNK001AML01, NCT04310592: Natural Killer Cell (CYNK-001) Infusions in Adults With AML

Recruiting
1
94
US
CYNK-001
Celularity Incorporated
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
06/24
12/24
NCT03844815: Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

Recruiting
1
26
US
Decitabine, Venetoclax
University of Chicago, AbbVie
Acute Myeloid Leukemia
06/24
06/25
NCT06291220: A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting
1
80
US, RoW
Obinutuzumab, ABBV-453
AbbVie
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
07/29
07/29
NCT05445765: Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

Not yet recruiting
1
10
RoW
anti-CD33 CAR T cells
iCell Gene Therapeutics, iCar Bio Therapeutics
Relapsed and/or Refractory Acute Myeloid Leukemia, High Risk Hematologic Malignancies
06/24
06/24
NCT05212584: CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Recruiting
1
24
RoW
CD7CAR T cells
iCell Gene Therapeutics, iCar Bio Therapeutics
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
06/24
06/24
NCR300-2002, NCT06441084: A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

Not yet recruiting
1
15
NA
NCR300 injection
Nuwacell Biotechnologies Co., Ltd., Beijing Friendship Hospital
Acute Myeloid Leukemia
12/28
12/31
NCT06357182: Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Recruiting
1
24
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, Iadademstat, ORY 1001, ORY-1001, RG 6016, RG6016, RO 7051790, RO7051790, trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
OHSU Knight Cancer Institute, Oregon Health and Science University, Oryzon Genomics S.A.
Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia
03/26
05/26
UCHMC 1812, NCT03904251: CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Checkmark From P1b trial in combination with Mylotarg for r/r AML at ASH 2020
Nov 2020 - Nov 2020: From P1b trial in combination with Mylotarg for r/r AML at ASH 2020
Terminated
1
13
US
Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Liposome-encapsulated Daunorubicin-Cytarabine, CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos
Jonsson Comprehensive Cancer Center, Pfizer, Jazz Pharmaceuticals, University of California, Los Angeles
Acute Myelogenous Leukemia
10/23
10/23
NCT04964505: Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Recruiting
1
25
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Uproleselan, GMI-1271, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Brian Jonas, GlycoMimetics Incorporated, National Cancer Institute (NCI)
Acute Myeloid Leukemia
07/24
01/25
NCT05292898: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Active, not recruiting
1
20
RoW
LCAR-AIO Cells
Institute of Hematology & Blood Diseases Hospital, China, Nanjing Legend Biotech Co.
Acute Lymphocytic Leukemia
07/24
07/26
NCT04657224: A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Active, not recruiting
1
75
Europe, US, RoW
JNJ-64264681, JNJ-67856633
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
07/25
07/25
LAUREL, NCT05933070: A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

Terminated
1
2
Europe
INKmune
Inmune Bio, Inc.
Cancer, MDS-EB, Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML
03/24
04/24
NCT05016947: Venetoclax Plus Inotuzumab for B-ALL

Recruiting
1
26
US
Venetoclax, Venclexta, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, Inotuzumab Ozogamicin, Besponsa
Dana-Farber Cancer Institute, AbbVie
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL
07/24
06/26
NCT05263271: Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Recruiting
1
58
RoW
Gentulizumab
GeneScience Pharmaceuticals Co., Ltd., Ruijin Hospital, Shanghai Tong Ren Hospital, First Affiliated Hospital of Zhejiang University
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
07/24
07/24
NCT04872478: Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Recruiting
1
50
US
MRX-2843
Meryx, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
07/24
12/24
NCT05424822: A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Recruiting
1
220
Europe, US, RoW
JNJ-80948543
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
07/24
11/26
NCT06158100: Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Not yet recruiting
1
25
US
Venetoclax, Venclexta, Venclyxto, Azacitidine, Vidaza, Azadine, Donor Lymphocyte Infusion
Antonio M Jimenez Jimenez, AbbVie
Acute Myeloid Leukemia
07/29
07/29
NCT06399640: Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Not yet recruiting
1
60
US
Eltanexor, KPT-8602, Venetoclax, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
Vanderbilt-Ingram Cancer Center, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/26
12/27
NCT02483312: A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Recruiting
1
9
Canada
IL-12
University Health Network, Toronto, Ozmosis Research Inc.
Acute Myeloid Leukemia
08/24
08/24
NCT03927261: PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Recruiting
1
88
US
PRGN-3006 T Cells
Precigen, Inc
Acute Myeloid Leukemia, Myelodysplastic Syndromes
08/24
08/25
NCT04653493: CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Not yet recruiting
1
22
RoW
CD19 CAR engineered autologous T-cells, Cyclophosphamide, Fludarabine, Mesna
Sabz Biomedicals, Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran, Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL), Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
08/24
08/24
NCT04771572: Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Recruiting
1
100
US
LP-118
Newave Pharmaceutical Inc
Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
10/25
10/25
NCT04328714: Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

Suspended
1
45
US
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Edwin Horwitz, Ossium Health, Inc.
Acute Leukemia, Myelodysplastic Syndromes
08/24
08/24
NCT04937166: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Recruiting
1
36
US
DSP107, Azacitidine, Vidaza, Venetoclax, Venclexta, Venclyxto
Kahr Medical
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
08/24
12/24
NCT05024552: Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Recruiting
1
22
US
Gilteritinib, Xospata, Vyxeos, daunorubicin-cytarabine
H. Lee Moffitt Cancer Center and Research Institute, Jazz Pharmaceuticals
Acute Myeloid Leukemia With FLT3/ITD Mutation
11/24
11/25
NCT05480501: Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Recruiting
1
9
RoW
IM19 CAR-T cells
Beijing Immunochina Medical Science & Technology Co., Ltd.
Leukemia
08/24
10/24
NCT04500587: Phase 1 First in Human Study of ZN-d5 as a Single Agent

Recruiting
1
115
Europe, RoW
ZN-d5, Study Drug
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Non Hodgkin Lymphoma
08/24
01/25
OMNIVERSE, NCT04887857: A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

Completed
1
6
US, RoW
CC-486, ONUREG®, oral azacitidine, Venetoclax, VENCLEXTA®, VENCLYXTO®
Celgene, AbbVie
Leukemia, Myeloid, Acute
01/24
01/24
QLF32101-101, NCT05703204: A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Not yet recruiting
1
122
RoW
QLF32101
Qilu Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia and Myelodysplastic Syndrome
08/24
12/24
NCT04709458: Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Not yet recruiting
1
10
Europe, RoW
TBX-2400
Taiga Biotechnologies, Inc.
Myelofibrosis, Acute Myelogenous Leukemia
08/24
10/24
NCT04240704 / 2019-002666-12: Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Active, not recruiting
1
25
Europe, Japan, RoW
JBH492
Novartis Pharmaceuticals
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
09/24
09/24
NCT05105867: CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Recruiting
1
15
RoW
Anti-CD19 Universal CAR-T Cells injection
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Gracell Biotechnology Shanghai Co., Ltd., Kunming Hope of Health Hospital
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B-cell Non-hodgkin Lymphoma
08/24
11/24
NCT05651178: Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Recruiting
1
20
RoW
Human CD19-CD22 Targeted T Cells Injection, CD19-CD22 CAR-T
Hrain Biotechnology Co., Ltd., Second Affiliated Hospital of Nanchang University
Central Nervous System Lymphoma
08/24
08/25
Encore-MDS, NCT02841540: A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

Terminated
1
127
Europe, US, RoW
H3B-8800 (RVT-2001)
Hemavant Sciences GmbH
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
02/24
02/24
NCT04072458: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Recruiting
1
30
US
L-Bcl-2 antisense oligonucleotide, BP1002
Bio-Path Holdings, Inc.
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Marginal Zone Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, DLBCL
09/24
01/26
KNAN2001, NCT04716452: Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Not yet recruiting
1
18
US
Ceramide NanoLiposome (Ceraxa), Ceramide NanoLiposome
Keystone Nano, Inc, University of Virginia, Milton S. Hershey Medical Center
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory
09/24
12/24
NCT06313437: Revumenib in Combination With 7+3 + Midostaurin in AML

Not yet recruiting
1
22
US
Revumenib, SNDX-5613, Trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2- yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide, Midostaurin, Rydapt, Cytarabine, cytosine arabinoside (ara-C), Daunorubicin, Daunomycin
Maximilian Stahl, MD, Syndax Pharmaceuticals
Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
03/26
03/27
NCT04629729: FT819 in Subjects With B-cell Malignancies

Recruiting
1
396
US
FT819, Cyclophosphamide, Fludarabine, Fludara, IL-2, Interleukin-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
09/24
09/39
NCT05651191: To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

Recruiting
1
9
RoW
Human CD19 Targeted DASH CAR-T Cells Injection, CD19 DASH CAR-T
Hrain Biotechnology Co., Ltd., Second Affiliated Hospital of Nanchang University
B-cell Acute Lymphoblastic Leukemia
09/24
09/25
XmAb13676-01, NCT02924402: Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Checkmark Presentation of data from trial for NHL at ASH 2022
Nov 2022 - Nov 2022: Presentation of data from trial for NHL at ASH 2022
Checkmark From trial for NHL and CLL at ASH 2021
Dec 2021 - Dec 2021: From trial for NHL and CLL at ASH 2021
Checkmark From trial in hematologic malignancies at ASH 2019
More
Active, not recruiting
1
270
Europe, US, RoW
XmAb13676
Xencor, Inc., ICON Clinical Research
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
10/24
01/25
ODYSSEY, NCT05601726: First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

Active, not recruiting
1
7
Europe
ABD-3001, DIMATE
Advanced BioDesign
Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes
10/24
12/24
NCT04207190: Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting
1
24
US
Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Talazoparib, BMN 673, BMN-673, Talazoparib Tosylate, Talzenna
Roswell Park Cancer Institute, Pfizer
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
04/25
04/25
NCT06397027: A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Not yet recruiting
1
22
US
Ziftomenib, Venetoclax, ABT-199, GDC-0199, Azacitidine, 5-azacytidine,, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, Azacytidine, NSC-102816
M.D. Anderson Cancer Center, Kura Oncology, Inc.
Refractory Acute Leukemia, Pediatric Relapsed
12/28
12/30
NCT06401603: A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Not yet recruiting
1
30
US
Decitabine, Dacogen, Listaftoclax, Olverembatinib
M.D. Anderson Cancer Center, Ascentage Pharma Group Inc.
Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia
01/27
01/29
NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Recruiting
1
41
RoW
GNC-038
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
11/24
11/24
NCT05775406: Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Recruiting
1
70
US
KT-253
Kymera Therapeutics, Inc.
Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
11/24
11/25
NCT06448013: A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Not yet recruiting
1
22
US
Venetoclax, ABT-199, GDC-0199, Gemtuzumab, Gemtuzumab ozogamicin, Mylotarg, Ziftomenib
M.D. Anderson Cancer Center, Kura Oncology, Inc.
Acute Myeloid Leukemia
12/28
12/30
NCT06445907: Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Not yet recruiting
1
32
US
Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine, Venetoclax, ABT-199, GDC-0199, Q702
M.D. Anderson Cancer Center, Qurient Co., Ltd.
Acute Myeloid Leukemia
07/26
07/28
CT071-CG7001, NCT05838131: Study of CT071 Injection in RRMM or PPCL

Recruiting
1
30
RoW
Experimental: CAR-T cells Infusion, Single Group Assignment
Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd.
Multiple Myeloma, Primary Plasma Cell Leukemia
11/24
11/24
NCT05963217: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Recruiting
1
19
Canada
TBI-2001, Cyclophosphamide, Fludarabine
University Health Network, Toronto, Takara Bio Inc.
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
03/25
05/26
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
74
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy
12/25
06/26
 

Download Options